{
  "schema_version": "1.0",
  "publisher": "AffordableCompoundedTirzepatide.com",
  "provider": "NexLife",
  "currency": "USD",
  "prices_verified_date": "2026-07-11",
  "verification_note": "Prices transcribed from NexLife's published self-pay program pages on 2026-07-11. Prices are set by NexLife and can change at any time. Always confirm the current price on the official program page before enrolling.",
  "math_rule": "monthly_equivalent = plan_total / plan_months. savings_vs_monthly = (monthly_rate * plan_months) - plan_total. Every displayed figure on this site is derived from this file.",
  "pricing_corrections_applied": [
    "Semaglutide microdose 3-month: source card showed $117/mo against a $357 total. $357 / 3 = $119. Corrected to $119/mo.",
    "Semaglutide ODT 3-month: source card showed $597 total with $185/mo and $42 savings, which cannot all be true. $185 x 3 = $555, and $199 x 3 - $555 = $42. Corrected total to $555.",
    "Tirzepatide microdose 3-month: $479 / 3 = $159.67, not $159. Displayed as approximately $160/mo.",
    "Tirzepatide microdose 6-month: $899 / 6 = $149.83, not $150. Displayed as approximately $150/mo with exact value retained."
  ],
  "program_inclusions_stated_by_nexlife": [
    "Same published program price at every covered dose",
    "No separate membership fee",
    "No hidden program fees",
    "Free expedited shipping",
    "Licensed-provider evaluation and ongoing medical oversight",
    "Coaching and patient community access"
  ],
  "regulatory": {
    "fda_status": "Compounded tirzepatide and compounded semaglutide are not FDA-approved.",
    "not_same_as_brand": "Compounded tirzepatide is not the same product as Mounjaro or Zepbound. Mounjaro and Zepbound are trademarks of Eli Lilly and Company.",
    "premarket_review": "Compounded medications do not undergo FDA premarket review for safety, effectiveness or quality.",
    "eligibility": "Prescription treatment requires evaluation and approval by a licensed healthcare provider. Availability varies by state, pharmacy and individual clinical need."
  },
  "programs": [
    {
      "id": "tirzepatide_standard",
      "medication": "tirzepatide",
      "form": "Standard injection",
      "official_url": "https://nexlife.com/pages/tirzepatide-all-plans",
      "monthly_rate": 215,
      "plans": [
        {
          "months": 1,
          "total": 215,
          "monthly_equivalent": 215,
          "monthly_display": "$215",
          "savings_vs_monthly": 0
        },
        {
          "months": 3,
          "total": 585,
          "monthly_equivalent": 195.0,
          "monthly_display": "$195",
          "savings_vs_monthly": 60
        },
        {
          "months": 6,
          "total": 1140,
          "monthly_equivalent": 190.0,
          "monthly_display": "$190",
          "savings_vs_monthly": 150
        },
        {
          "months": 12,
          "total": 2232,
          "monthly_equivalent": 186.0,
          "monthly_display": "$186",
          "savings_vs_monthly": 348
        }
      ]
    },
    {
      "id": "tirzepatide_microdose",
      "medication": "tirzepatide",
      "form": "Microdose",
      "official_url": "https://nexlife.com/pages/microdose-tirzepatide-program",
      "monthly_rate": 189,
      "plans": [
        {
          "months": 1,
          "total": 189,
          "monthly_equivalent": 189,
          "monthly_display": "$189",
          "savings_vs_monthly": 0
        },
        {
          "months": 3,
          "total": 479,
          "monthly_equivalent": 159.67,
          "monthly_display": "~$160",
          "savings_vs_monthly": 88
        },
        {
          "months": 6,
          "total": 899,
          "monthly_equivalent": 149.83,
          "monthly_display": "~$150",
          "savings_vs_monthly": 235
        },
        {
          "months": 12,
          "total": 1764,
          "monthly_equivalent": 147.0,
          "monthly_display": "$147",
          "savings_vs_monthly": 504
        }
      ]
    },
    {
      "id": "tirzepatide_odt",
      "medication": "tirzepatide",
      "form": "Oral tablet / ODT",
      "official_url": "https://nexlife.com/pages/tirzepatide-oraltablet-program",
      "monthly_rate": 229,
      "plans": [
        {
          "months": 1,
          "total": 229,
          "monthly_equivalent": 229,
          "monthly_display": "$229",
          "savings_vs_monthly": 0
        },
        {
          "months": 3,
          "total": 657,
          "monthly_equivalent": 219.0,
          "monthly_display": "$219",
          "savings_vs_monthly": 30
        },
        {
          "months": 6,
          "total": 1230,
          "monthly_equivalent": 205.0,
          "monthly_display": "$205",
          "savings_vs_monthly": 144
        },
        {
          "months": 12,
          "total": 2388,
          "monthly_equivalent": 199.0,
          "monthly_display": "$199",
          "savings_vs_monthly": 360
        }
      ]
    },
    {
      "id": "semaglutide_standard",
      "medication": "semaglutide",
      "form": "Standard injection",
      "official_url": "https://nexlife.com/pages/semaglutide-all-plans",
      "monthly_rate": 165,
      "plans": [
        {
          "months": 1,
          "total": 165,
          "monthly_equivalent": 165,
          "monthly_display": "$165",
          "savings_vs_monthly": 0
        },
        {
          "months": 3,
          "total": 447,
          "monthly_equivalent": 149.0,
          "monthly_display": "$149",
          "savings_vs_monthly": 48
        },
        {
          "months": 6,
          "total": 882,
          "monthly_equivalent": 147.0,
          "monthly_display": "$147",
          "savings_vs_monthly": 108
        },
        {
          "months": 12,
          "total": 1740,
          "monthly_equivalent": 145.0,
          "monthly_display": "$145",
          "savings_vs_monthly": 240
        }
      ]
    },
    {
      "id": "semaglutide_microdose",
      "medication": "semaglutide",
      "form": "Microdose",
      "official_url": "https://nexlife.com/pages/microdose-semaglutide-program",
      "monthly_rate": 129,
      "plans": [
        {
          "months": 1,
          "total": 129,
          "monthly_equivalent": 129,
          "monthly_display": "$129",
          "savings_vs_monthly": 0
        },
        {
          "months": 3,
          "total": 357,
          "monthly_equivalent": 119.0,
          "monthly_display": "$119",
          "savings_vs_monthly": 30
        },
        {
          "months": 6,
          "total": 684,
          "monthly_equivalent": 114.0,
          "monthly_display": "$114",
          "savings_vs_monthly": 90
        },
        {
          "months": 12,
          "total": 1320,
          "monthly_equivalent": 110.0,
          "monthly_display": "$110",
          "savings_vs_monthly": 228
        }
      ]
    },
    {
      "id": "semaglutide_odt",
      "medication": "semaglutide",
      "form": "Oral tablet / ODT",
      "official_url": "https://nexlife.com/pages/semaglutide-oraltablet-program",
      "monthly_rate": 199,
      "plans": [
        {
          "months": 1,
          "total": 199,
          "monthly_equivalent": 199,
          "monthly_display": "$199",
          "savings_vs_monthly": 0
        },
        {
          "months": 3,
          "total": 555,
          "monthly_equivalent": 185.0,
          "monthly_display": "$185",
          "savings_vs_monthly": 42
        },
        {
          "months": 6,
          "total": 1062,
          "monthly_equivalent": 177.0,
          "monthly_display": "$177",
          "savings_vs_monthly": 132
        },
        {
          "months": 12,
          "total": 1980,
          "monthly_equivalent": 165.0,
          "monthly_display": "$165",
          "savings_vs_monthly": 408
        }
      ]
    }
  ],
  "clinical_trials_fda_approved_injectable_only": [
    {
      "study": "SURMOUNT-1",
      "treatment": "Tirzepatide (FDA-approved injectable)",
      "dose": "5 mg",
      "duration_weeks": 72,
      "population": "Adults with obesity or overweight, without type 2 diabetes (N=2,539)",
      "estimand": "Treatment-regimen (mean % change from baseline)",
      "mean_weight_change_pct": -15.0,
      "source": "Jastreboff AM et al. N Engl J Med. 2022;387:205-216"
    },
    {
      "study": "SURMOUNT-1",
      "treatment": "Tirzepatide (FDA-approved injectable)",
      "dose": "10 mg",
      "duration_weeks": 72,
      "population": "Adults with obesity or overweight, without type 2 diabetes (N=2,539)",
      "estimand": "Treatment-regimen (mean % change from baseline)",
      "mean_weight_change_pct": -19.5,
      "source": "Jastreboff AM et al. N Engl J Med. 2022;387:205-216"
    },
    {
      "study": "SURMOUNT-1",
      "treatment": "Tirzepatide (FDA-approved injectable)",
      "dose": "15 mg",
      "duration_weeks": 72,
      "population": "Adults with obesity or overweight, without type 2 diabetes (N=2,539)",
      "estimand": "Treatment-regimen (mean % change from baseline)",
      "mean_weight_change_pct": -20.9,
      "source": "Jastreboff AM et al. N Engl J Med. 2022;387:205-216"
    },
    {
      "study": "SURMOUNT-1",
      "treatment": "Placebo",
      "dose": "n/a",
      "duration_weeks": 72,
      "population": "Adults with obesity or overweight, without type 2 diabetes (N=2,539)",
      "estimand": "Treatment-regimen (mean % change from baseline)",
      "mean_weight_change_pct": -3.1,
      "source": "Jastreboff AM et al. N Engl J Med. 2022;387:205-216"
    },
    {
      "study": "SURMOUNT-5",
      "treatment": "Tirzepatide (FDA-approved injectable)",
      "dose": "Maximum tolerated (10 or 15 mg)",
      "duration_weeks": 72,
      "population": "Adults with obesity, without type 2 diabetes; head-to-head vs semaglutide",
      "estimand": "Mean % change from baseline",
      "mean_weight_change_pct": -20.2,
      "source": "Aronne LJ et al. N Engl J Med. 2025 (SURMOUNT-5)"
    },
    {
      "study": "SURMOUNT-5",
      "treatment": "Semaglutide (FDA-approved injectable)",
      "dose": "Maximum tolerated (1.7 or 2.4 mg)",
      "duration_weeks": 72,
      "population": "Adults with obesity, without type 2 diabetes; head-to-head vs tirzepatide",
      "estimand": "Mean % change from baseline",
      "mean_weight_change_pct": -13.7,
      "source": "Aronne LJ et al. N Engl J Med. 2025 (SURMOUNT-5)"
    }
  ],
  "clinical_evidence_limitation": "These results come from clinical trials of FDA-approved injectable products. They do not establish the safety or effectiveness of a compounded, microdose or oral/ODT formulation. Individual results vary."
}